In breast cancer, we and other groups have demonstrated the oncosuppressive role of miR-205, which is able to directly target HER3, thus improving the responsiveness to tyrosin-kinase inhibitors (TKIs) [28] and Trastuzumab [29] in HER2+ breast cancer cell lines. Here, ERBB2 is linked to breast cancer.